IP Library Granted Patent US 8,518,699
Granted Patent B2
US 8,518,699 · App. 10/590,211 · Granted Aug 27, 2013

Methods for genetic diversification in gene conversion active cells

Inventors: Jean-Marie Buerstedde (München, DE); Hiroshi Arakawa (München, DE)
Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit, GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,518,699
App. No.
10/590,211
Granted
Aug 27, 2013
Kind
B2
Abstract

The invention relates to a modified lymphoid cell having gene conversion fully or partially replaced by hypermutation, wherein said cell has no deleterious mutations in genes encoding paralogues and analogues of the RAD51 protein, and wherein said cell is capable of directed and selective genetic diversification of a target nucleic acid by hypermutation or a combination of hypermutation and gene conversion. The invention also relates to a method for diversifying any transgenic target gene in said cell. Preferably, the target gene is integrated into the immunoglobulin light or heavy chain locus by targeted integration.

Claims (28)

1. A method for producing a hypermutated transgenic target nucleic acid sequence comprising

a) transfecting a chicken immunoglobulin expressing B lymphoid cell with a genetic construct comprising a target nucleic acid sequence flanked by nucleic acid sequences homologous to an endogenous V gene immunoglobulin locus;

b) integrating said genetic construct comprising said target nucleic acid sequence into said endogenous V gene immunoglobulin locus of said chicken immunoglobulin expressing B lymphoid cell, wherein said chicken immunoglobulin expressing B lymphoid cell comprises a functional activation-induced deaminase (AID) protein, and functional XRCC2, XRCC3, and RAD51 proteins or their analogues; and

c) culturing said chicken immunoglobulin expressing B lymphoid cell transgenic for said target nucleic acid to produce said hypermutated transgenic target nucleic acid sequence.

2. The method according to claim 1 , wherein an endogenous V-gene segment or a fragment thereof in said endogenous V-gene immunoglobulin locus of said chicken immunoglobulin expressing B lymphoid cell is replaced with said transgenic target nucleic acid sequence.

3. The method according to claim 1 , wherein said chicken immunoglobulin expressing B lymphoid cell is capable of homologous recombination and DNA repair.

4. The method according to claim 1 , wherein said chicken immunoglobulin expressing B lymphoid cell is a chicken Bursal lymphoma cell.

5. The method according to claim 1 , wherein said chicken immunoglobulin expressing B lymphoid cell is a DT40 cell or a derivative thereof.

6. The method according to claim 1 , wherein said target nucleic acid sequence encodes a protein or possesses a regulatory activity.

7. The method according to claim 1 , wherein said target nucleic acid sequence encodes a protein selected from the group consisting of an immunoglobulin chain, a selection marker, a DNA-binding protein, a DNA-binding protein fragment, an enzyme, a receptor protein, and a receptor protein fragment.

8. The method according to claim 1 , wherein said target nucleic acid sequence is a human immunoglobulin V-gene segment or a part thereof.

9. The method according to claim 1 , wherein said target nucleic acid sequence comprises a transcription regulatory element or an interfering RNA (RNAi) sequence.

10. The method according to claim 9 , wherein said transcription regulatory element is a promoter.

11. The method according to claim 1 , further comprising (d) identifying said chicken immunoglobulin expressing B lymphoid cell containing said hypermutated transgenic target nucleic acid sequence.

12. The method according to claim 11 , wherein said identifying said chicken immunoglobulin expressing B lymphoid cell containing said hypermutated transgenic target nucleic acid sequence comprises identifying a protein encoded by said hypermutated transgenic target nucleic acid sequence on the surface of said chicken immunoglobulin expressing B lymphoid cell, within said chicken immunoglobulin expressing B lymphoid cell, or outside of said chicken immunoglobulin expressing B-lymphoid cell.

13. The method according to claim 1 , further comprising modulating hypermutation of said target nucleic acid sequence with a DNA repair or recombination factor other than a XRCC2, XRCC3, and RAD51 protein or their analogue.

14. The method according to claim 13 , wherein said DNA repair or recombination factor is a RAD54 protein.

15. The method according to claim 1 , wherein said chicken immunoglobulin expressing B lymphoid cell has no pseudo-V gene segment.

16. The method according to claim 1 , wherein hypermutation is at a rate above an order of 10 −9 to 10 −10 bp −1 generation −1 .

17. The method according to claim 1 , wherein hypermutation is at a rate between 10 −5 to 10 −3 bp −1 generation −1 .

18. The method according to claim 11 , wherein a gene product of said hypermutated transgenic target nucleic acid sequence has an optimized desired activity.

19. The method according to claim 11 , wherein said identifying further comprises (e) culturing said chicken immunoglobulin expressing B lymphoid cell under appropriate conditions to express a mutated gene product encoded by said hypermutated transgenic target nucleic acid sequence; (f) identifying said cultured chicken immunoglobulin expressing B lymphoid cell that expresses said mutated gene product having a desired activity; (g) establishing a clonal population of cells from said cultured chicken immunoglobulin expressing B lymphoid cell; and (h) selecting from said clonal population a cell that expresses a gene product of said hypermutated transgenic target nucleic acid sequence having an improved desired activity.

20. The method according to claim 19 , wherein steps (f) through (h) are iteratively repeated.

21. The method according to claim 19 , further comprising inhibition of hypermutation.

22. The method according to claim 21 , wherein said inhibition of hypermutation is by down-regulation of the expression of a trans-acting regulatory factor.

23. The method according to claim 22 , wherein said trans-acting regulatory factor is activation-induced deaminase (AID).

24. The method according to claim 5 , wherein said chicken immunoglobulin expressing B lymphoid cell has no pseudo-V gene segment.

25. The method according to claim 1 , wherein said chicken immunoglobulin expressing B lymphoid cell is a DT40 AID R ΨV − cell.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2016
From: HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESENDHEIT UND UMWELT (GMBH)
To: CHIOME BIOSCIENCE, INC.
Reel/Frame 038840/0203 →
CHANGE OF NAME Recorded Mar 29, 2016
From: GSF FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT, GMBH
To: HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH)
Reel/Frame 038284/0040 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2006
From: BUERSTEDDE, JEAN-MARIE; ARAKAWA, HIROSHI
To: GSF-FORSCHUNGSZENTRUM FUR UMWELT AND GESUNDHEIT, GMBH
Reel/Frame 018220/0611 →
CORRECTIVE ASSIGNMENT TO CORRECT THE COVER SHEET RECEIVING PARTY NAME TO "... UND GESUNDHEIT GMBH"; COVER SHEET RECEIVING PARTY STREET ADDRESS TO "... LANDSTRASSE 1" PREVIOUSLY RECORDED ON REEL 018220 FRAME 0611. ASSIGNOR(S) HEREBY CONFIRMS THE TRANSFER AS IN THE EXECUTED ASSIGNMENT. Recorded Sep 8, 2006
From: BUERSTEDDE, JEAN-MARIE; ARAKAWA, HIROSHI
To: GSF-FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT, GMBH
Reel/Frame 018230/0219 →
Priority Claims (1)
EP 004004062 · Feb 23, 2004 · regional
Continuity (1)
Related Publication 20070186292A1 · Aug 9, 2007